GHK-Cu side effects depend on the route. Topical copper-peptide cosmetics are generally well tolerated, although redness, dryness, itching or stinging can occur. Injectable compounded GHK-Cu has much less human evidence. Local pain, redness, swelling and bruising are plausible and reported; transient light-headedness or low blood pressure appears in anecdotal accounts, not measured trial rates. No long-term human injection study tells us how often these effects happen.
That distinction matters more than any single symptom list. Evidence from a face cream cannot establish the safety of a substance injected under the skin. For the compound's proposed pathways and studied uses, rather than duplicating them here, see what GHK-Cu does.
GHK-Cu side effects depend on topical versus injectable use
Topical GHK-Cu, often listed on cosmetics as copper tripeptide-1, is used at very low concentrations and mostly stays within the skin barrier. An injection bypasses that barrier and introduces a compounded preparation into tissue, where exposure, formulation sterility and individual health history become separate safety questions.
The routes also have different evidence bases:
| Route | Human evidence | Effects that can reasonably be discussed |
|---|---|---|
| Topical cosmetic | Decades of cosmetic use; small skin and wound studies | Usually mild local irritation, redness, itching, dryness or sensitivity |
| Compounded injection | No published controlled long-term human safety study | Local injection reactions; systemic reports are anecdotal and have no reliable incidence rate |
The absence of a signal in topical use is therefore reassuring only for topical products at the concentrations studied. It does not transfer to an injectable vial.
What the topical evidence actually shows
A 2018 cosmetic-ingredient safety assessment included copper tripeptide-1 and concluded that the peptide family was safe as used in cosmetics at the low concentrations reviewed. The report's human patch tests were largely on related GHK derivatives, however, so it does not provide a clean GHK-Cu irritation percentage (Johnson et al., International Journal of Toxicology, 2018).
The clinical literature is similarly limited. A multicenter randomized trial tested topical GHK-Cu gel in diabetic ulcers, while a later randomized study had only 13 people complete it after carbon-dioxide laser resurfacing. The laser study found no objective advantage for redness resolution and did not establish a general adverse-event rate (Mulder et al., Wound Repair and Regeneration, 1994; Miller et al., Archives of Facial Plastic Surgery, 2006).
The practical reading is narrow: irritation from topical products appears uncommon and usually mild, but the exact rate depends on the complete formula and is poorly reported. A 2025 review found no published studies designed specifically to measure side effects of topical GHK derivatives (Mortazavi et al., BioImpacts, 2025). A reaction to a serum may also come from its fragrance, preservative or another active rather than the copper peptide alone.
What is known about GHK-Cu injection side effects
For injections, the honest answer is that a formal side-effect table does not exist. Two major Pickart reviews summarize extensive cell, animal and topical work, but neither supplies controlled human safety rates for subcutaneous use (Pickart et al., BioMed Research International, 2015; Pickart and Margolina, International Journal of Molecular Sciences, 2018).
Pain, stinging, redness, a small welt, swelling or bruising can occur where any subcutaneous injection enters the skin. There is no sound evidence for assigning GHK-Cu-specific percentages to those reactions. Transient light-headedness and lower blood pressure are also described by patients and prescribers, but those reports are anecdotal. They cannot establish frequency, dose dependence or causation.
A blend makes attribution harder. If symptoms begin after a multi-peptide formulation, the reaction cannot automatically be assigned to its GHK-Cu component. The KLOW peptide blend guide owns the formulation overview, and the separate KPV guide covers that ingredient rather than folding it into this side-effect profile.
How much copper is in GHK-Cu?
GHK-Cu is a one-to-one complex of a peptide and a copper ion. Using a molecular mass of about 402.9 grams per mole for the complex and 63.546 for copper, copper accounts for about 15.8% of its mass. The arithmetic is:
1 mg GHK-Cu × 63.546 ÷ 402.9 = 0.158 mg copper, or about 158 micrograms.
That amount is about 18% of the adult dietary allowance of 900 micrograms and 1.6% of the adult oral upper limit of 10 milligrams (Burkhead and Collins, Advances in Nutrition, 2022). It is a small absolute copper load per milligram of GHK-Cu, not a full milligram of copper.
This comparison is context, not proof of injectable safety. Dietary limits were built for copper swallowed over time; oral absorption is incomplete, while injection bypasses the gut. Total exposure also includes food, supplements and any other copper-containing product. A prescriber may give extra scrutiny to Wilson disease, other disorders of copper handling, liver or biliary disease, and unexplained abnormal copper studies.
What a prescriber weighs before treatment
GHK-Cu has no FDA-approved use. The injectable formulation is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision is between the patient and the doctor.
At Promise, a licensed provider reviews every request and not everyone qualifies. The review should account for copper-metabolism and liver history, medications and supplements, prior reactions to injections, pregnancy or breastfeeding, and whether new symptoms warrant evaluation before treatment rather than attribution to a peptide.
Long-term uncertainty is part of that decision. There is no published human injection study that follows copper status, liver measures, blood pressure and adverse events over months or years. A normal first few injections cannot answer that missing question.
When a reaction needs medical attention
Brief local tenderness is different from a spreading or systemic reaction. Increasing redness, warmth, drainage, fever, persistent dizziness or repeated near-fainting warrants prompt contact with the treating clinician. Facial or throat swelling, trouble breathing, fainting, confusion or other severe symptoms require urgent medical assessment.
Follow-up is where a provider can decide whether the pattern fits an injection reaction, another ingredient, infection, blood-pressure change or an unrelated condition. Without that assessment, simply calling every symptom a copper-peptide effect can delay the right care.